As patients spend between N300,000 and N350,000 monthly on medication, alongside costly diagnostic procedures and limited access to specialised care, advocates for people living with pulmonary hypertension have urged government to include the condition in Nigeria’s health insurance coverage.
The Founder and Executive Director of the Cardiac Community Advocacy and Support Initiative, Ayotunde Omitogun, told The Guardian that inadequate insurance coverage, poor awareness and limited availability of essential medicines were worsening the burden on patients.
Omitogun, who has lived with the condition for 13 years, said pulmonary hypertension required lifelong treatment, leaving patients to bear the cost of medicines and regular medical investigations.
She explained that pulmonary hypertension, characterised by abnormally high blood pressure in the arteries connecting the heart to the lungs, differs from systemic hypertension, which affects blood vessels throughout the body.
The condition can develop from underlying diseases, including congenital heart defects, sickle cell disease, HIV and left-sided heart disease, although some forms are classified as rare diseases.
Omitogun said pulmonary hypertension remained poorly understood in Nigeria, with symptoms often mistaken for asthma and tuberculosis. These include breathlessness, fatigue, chest pain and coughing.
She warned that without appropriate treatment, the condition could progressively damage the heart and lungs, leading to heart failure and death.
Patients may also struggle with routine activities such as walking short distances, climbing stairs and speaking for extended periods. Some require supplementary oxygen, while women living with the condition are generally advised against pregnancy because of potentially fatal complications.
On diagnosis, Omitogun said patients undergo several investigations, including electrocardiograms, echocardiograms, chest X-rays and CT scans, while right heart catheterisation remains the gold-standard procedure for confirming the condition.
She lamented that government hospitals rarely had the medicines needed to manage pulmonary hypertension, forcing patients to source them from private suppliers.
According to her, patients taking Bosentan, an endothelin receptor antagonist, could spend between N300,000 and N350,000 monthly on the drug.
She said her own treatment involved six or seven medicines because of accompanying heart failure, requiring additional drugs such as blood thinners and diuretics.
Her monthly medication expenses range from N400,000 to N500,000, despite using generic medicines rather than branded alternatives.
Omitogun said health insurance schemes in Nigeria provided inadequate coverage for the condition, leaving patients to finance most of their treatment out of pocket.
She also highlighted the link between pulmonary hypertension and sickle cell disease, explaining that the former could develop as a complication of the latter, although not everyone with sickle cell disease would develop it.
On the activities of the Cardiac Community Advocacy and Support Initiative, she said the organisation focused on raising awareness, building a support network for Nigerians living with pulmonary hypertension and helping patients obtain essential medicines through its drug assistance programme.
She added that the organisation was training primary healthcare workers to recognise symptoms and refer suspected cases to appropriate health facilities.
Omitogun urged government to improve healthcare infrastructure, develop policies to support the diagnosis and treatment of rare diseases, and expand health insurance coverage to include chronic conditions such as pulmonary hypertension.
She said although rare diseases might affect relatively few people, their impact on patients and families could be devastating.